Pharma Solutions has bought a revolution in the treatment of Thalassemia in the UAE by introducing a new drug that will cut the treatment cost by 40%. Manufactured in Switzerland, the medicine will be launched in the UAE by Pharma Solutions.
With the highest carrier frequency of 49% in the UAE, thalassemia continued to be a potential health threat to the patients. The cost of treatment was an added burden to the patients. Pharma Solutions has stepped in providing relief to the patients.
Deferiprone is an iron chelator used in the treatment of patients with transfusion iron overload due to thalassemia syndromes when the current chelation therapy is inadequate.
In a conversation with Khaleej Times, Mr. Khurshid Zaidi the Managing Director of Pharma Solutions
sounds very positive to fight back this deadly disease with the new drug. He further talks about his vision to strengthen the UAE’s healthcare against all the odds.
To read the complete press coverage visit the respective links below: